Creative Medical Technology Holdings, Inc.
CELZ- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001187953
No open-market purchases or sales by Creative Medical Technology Holdings, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $540.7K in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Creative Medical Technology Holdings, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 9
- −6 vs. Q1 2023
- Shares held
- 20.8K
- −329.4K (−94.1%) vs. Q1 2023
- Total value
- $96.4K
- −$79.4K (−45.2%) vs. Q1 2023
- New holders
- 2
- 1 more added
- Sold out
- 8
- 6 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CELZ on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 15 | $540.7K |
| Q1 2026 | 11 | $199.3K |
| Q4 2025 | 14 | $252.6K |
| Q3 2025 | 12 | $233.4K |
| Q2 2025 | 12 | $185.4K |
| Q1 2025 | 11 | $437.1K |
| Q4 2024 | 8 | $71.2K |
| Q3 2024 | 10 | $213.8K |
| Q2 2024 | 9 | $267.0K |
| Q1 2024 | 13 | $552.1K |
| Q4 2023 | 8 | $90.5K |
| Q3 2023 | 8 | $104.3K |
| Q2 2023 | 9 | $96.5K |
| Q1 2023 | 15 | $176.3K |
| Q4 2022 | 19 | $157.1K |
| Q3 2022 | 18 | $258.0K |
| Q2 2022 | 15 | $1.13M |
| Q1 2022 | 15 | $736.0K |
| Q4 2021 | 10 | $625.0K |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Creative Medical Technology Holdings, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 17,629 | $81.7K | 0.00% | −43,421−71.1% | Reduced |
| Tower Research Capital LLC (TRC) | 2,053 | $9.52K | 0.00% | −7,177−77.8% | Reduced |
| Federation des caisses Desjardins du Quebec | 1,000 | $4.63K | 0.00% | −9,000−90.0% | Reduced |
| IFP Advisors, Inc | 55 | $322 | 0.00% | +5+10.0% | Added |
| Morgan Stanley | 20 | $93 | 0.00% | −180−90.0% | Reduced |
| UBS Group AG | 20 | $93 | 0.00% | +20 | New |
| Wells Fargo & Company | 10 | $46 | 0.00% | −87−89.7% | Reduced |
| Advisor Group Holdings, Inc. | 2 | $9 | 0.00% | −10−83.3% | Reduced |
| O'Dell Group, LLC | 1 | $5 | 0.00% | +1 | New |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −124,224−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −51,832−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −27,581−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −25,467−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −21,366−100.0% | Sold out |
| Northern Trust Corp | 0 | $0 | 0.00% | −17,060−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −1,075−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −915−100.0% | Sold out |